Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population‐Based Propensity‐Score‐Adjusted Analysis
Helicobacter · 2025
DOI: 10.1111/hel.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2025. Verfasst von Asaf Ness und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine E, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Helicobacter Infections, Glucagon-Like Peptides, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists delay gastric emptying and are used for the treatment of diabetes (DM) and obesity. Successful treatment of Helicobacter pylori ( H. pylori ) infection depends upon a precise dosing schedule. We aimed to examine the impact of GLP‐1 drugs on antibiotic treatment for H. pylori .
Methods
Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database. Subjects were divided into groups based on diagnoses of DM and obesity, and exposure to GLP‐1 drugs. A 1:2 propensity‐score matched dataset was used to determine the effect of GLP‐1 drugs on eradication success.
Results
We identified 426 individuals who received, and 36,436 who did not receive GLP‐1 drugs. Eradication among those who did and did not receive GLP‐1 drugs was 86.6% and 83.7%, respectively ( p = 0.059 across subgroups). Eradication among those who received semaglutide was 93.8% (OR 2.78, 95% CI 1.32–5.83, p = 0.007). Eradication in subjects who received dulaglutide (88.6%) or liraglutide (81.4%) was not significantly changed. When applying a propensity‐score‐adjusted analysis, eradication remained significantly increased among individuals who received semaglutide (OR 2.89, 95% CI 1.24–6.74, p = 0.014). Additional independent predictors of successful eradication included male sex, high socioeconomic status, quadruple therapy, and older age ( p < 0.001 for all).
Conclusions
Co‐administration of semaglutide and antibiotics for H. pylori infection is associated with an increased likelihood of successful eradication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine E, Rabin Medical Center, Petah Tikva, Israel.
- Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
ORCID-Profile: Doron Boltin
Zitieren
APA
Ness, A., Levi, Z., Belfer, R. G., Dickman, R., & Boltin, D. (2025). Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population‐Based Propensity‐Score‐Adjusted Analysis. Helicobacter. https://doi.org/10.1111/hel.70014
Vancouver
Ness A, Levi Z, Belfer RG, Dickman R, Boltin D. Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population‐Based Propensity‐Score‐Adjusted Analysis. Helicobacter. 2025. doi:10.1111/hel.70014
BibTeX
@article{Ness2025,
author = {Ness, Asaf and Levi, Zohar and Belfer, Rachel Gingold and Dickman, Ram and Boltin, Doron},
title = {Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population‐Based Propensity‐Score‐Adjusted Analysis},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70014}
}
EUVIMED